Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8252W HIGH $11.94
Volume
86.89 K
Value Traded
13.25 M
Short % Float
14.66%
-0.45%Week
+2.87%1 Month
+11.65%3 Month
+17.05%6 Month
-80%5 Year
-43.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.90 B
EPS (TTM)
-1.49
P/E Ratio
-
Ent. Value
1.35 B
Total Shares
169.22 M
Float Shares
134.07 M
Insiders
20.77%
Institutions
68.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
VIR Catalyst Timeline
Dated clinical, regulatory and corporate events for Vir Biotechnology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vir Biotechnology, Inc.
565Total events
14Upcoming
157Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationVIR-5500Designation
FDA grants Fast Track designation to VIR-5500 for late-line mCRPC
late-line metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Management ChangeCorporate
Aziz Sawaf appointed Executive Vice President and Chief Financial Officer
▲First Patient DosedVIR-5525Trial
First patient dosed in Phase 1 study of VIR-5525
EGFR-expressing solid tumorssource ↗
▲Enrollment CompleteTobevibartTrial
First patients enrolled in ECLIPSE 2
chronic hepatitis deltasource ↗
▲IND ClearanceVIR-5500IND
FDA clearance for VIR-5500 combination with androgen receptor pathway inhibitors
metastatic castration-resistant prostate cancersource ↗
◆Management ChangeCorporate
Brent Sabatini appointed Interim Principal Financial Officer; Jason O'Byrne departing
●Oral PresentationPresentation
Vir Biotechnology to participate in Bank of America Securities 2026 Healthcare Conference
▲Full ResultsElebsiranClinical Data
Complete Week 96 Phase 2 SOLSTICE data presented at EASL Congress
chronic hepatitis delta (CHD)source ↗
▲Partnership / LicenseVIR-5500Corporate
Global strategic collaboration with Astellas closed
metastatic prostate cancersource ↗
▲Milestone PaymentVIR-5500Corporate
Near-term $20 million milestone payment upon closing
metastatic prostate cancersource ↗
▲Partnership / LicenseCorporate
Closing of global strategic collaboration with Astellas for prostate cancer
prostate cancersource ↗
▲First Patient DosedVIR-5500Trial
First patient dosed in Phase 1 dose-expansion cohort (monotherapy) for VIR-5500
metastatic prostate cancersource ↗
▲First Patient DosedVIR-5500Trial
First patient dosed in Phase 1 dose-expansion cohorts of VIR-5500
metastatic prostate cancersource ↗
◆Trial InitiationVIR-5500Trial
Initiation of combination dose-expansion cohorts in early-line mCRPC and mHSPC
metastatic castration-resistant prostate cancersource ↗
▲Partnership / LicenseCorporate
Closed global strategic collaboration with Astellas for VIR-5500
prostate cancersource ↗
●Milestone PaymentCorporate
$48.0 million milestone payment to Sanofi triggered by closing of Astellas agreement
▼Equity OfferingCorporate
Pricing of underwritten public offering of 17,647,058 shares at $8.50 per share for gross proceeds of $150 million
◆Oral PresentationVIR-5500Presentation
Oral presentation at 2026 ASCO Genitourinary Cancers Symposium
metastatic castration-resistant prostate cancersource ↗
▼Equity OfferingCorporate
Proposed public offering of $200M common stock with $30M over-allotment option
▲Enrollment UpdateVIR-5500Trial
Updated Phase 1 dose-escalation data (n=58) reported
metastatic castration-resistant prostate cancersource ↗
▲Partnership / LicenseVIR-5500Corporate
Global strategic collaboration with Astellas for VIR-5500
prostate cancersource ↗
▲Topline ReadoutVIR-5500Clinical Data
Updated VIR-5500 Phase 1 dose-escalation data reported
solid tumorssource ↗
▲Partnership / LicenseVIR-5500Corporate
Global strategic collaboration with Astellas to co-develop and co-commercialize VIR-5500
prostate cancersource ↗
▲Oral PresentationVIR-5500Presentation
Safety and efficacy data presented at 2026 ASCO Genitourinary Cancers Symposium
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Full ResultsVIR-5500Clinical Data
Comprehensive VIR-5500 data update in late-line patients expected in Q1 2026
metastatic castration-resistant prostate cancersource ↗
▲Topline ReadoutVIR-5500Clinical Data
Phase 1 data for VIR-5500 reported earlier this year
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Partnership / LicenseTobevibartCorporate
License agreement with Norgine for tobevibart and elebsiran
chronic hepatitis deltasource ↗
◆Oral PresentationTobevibartPresentation
Week 48 endpoint results from SOLSTICE Phase 2 at AASLD 2025
chronic hepatitis deltasource ↗
▲Enrollment CompleteTobevibartTrial
ECLIPSE 1 enrollment completed approximately two months ahead of schedule
chronic hepatitis deltasource ↗
▲First Patient DosedVIR-5500Trial
First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs in first-line mCRPC
metastatic castration-resistant prostate cancersource ↗
●IND SubmissionVIR-1949IND
IND filing expected within next 18 months for VIR-1949
precancerous lesions caused by HPVsource ↗
●IND SubmissionVIR-2981IND
IND filing expected within next 18 months for VIR-2981
influenza A and Bsource ↗
●IND SubmissionVIR-8190IND
IND filing expected within next 18 months for VIR-8190 and other mAbs
RSV and/or metapneumovirussource ↗
▲Milestone PaymentVIR-5525Corporate
$75 million milestone payment triggered by VIR-5525 first-in-human dosing
solid tumorssource ↗
▲Enrollment CompleteTobevibartTrial
First patients enrolled in ECLIPSE 2
chronic hepatitis deltasource ↗
Past FDA Catalysts and PDUFA Decisions
How VIR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-01-08 | VIR-5818, VIR-5500 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C59 / 100
Pipeline Score
$937M
Pipeline Value
Overvalued
Valuation Signal
7
Drugs Scored
0.5x
rNPV / MCap
Top 8%
Micro Cap(rank 54 of 658)
Percentile Rank
Vir Biotechnology, Inc. carries a moderate pipeline score (59/100), with $2.3B risk-adjusted pipeline value, led by Tobevibart in Viral Hepatitis (Phase 3), across $166B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tobevibart Small moleculeNCT07142811 | Viral Hepatitis | Phase 3 | ACTIVE NOT_RECRUITING | 374 | Jul 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every VIR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VIR-5500 Fast Track | metastatic prostate cancer | Phase 1 | 2026-02-24 | PSA50 declines: 82%; PSA90 declines: 53%; ORR: 45%Read More | Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Napolitano JanetDirector | Sell | -3,200 21,216 held | $9.45 | 06/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VIR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 1.4 % (-36.4 %) | 19.01 M | 1.87 M |
VIR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VIR ranks across every disease it competes in
Competitive Position is a premium feature
See how VIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVIR News
VIR▲ +3.1%today
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Vir Biotechnology announced that the FDA has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager. This designation is specifically for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). The drug is being co-developed with Astellas Pharma, indicating a strong partnership in its advancement.
Read more →VIR▲ +3.1%today
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology has appointed Dr. David Liu as its new Chief Medical Officer, effective October 12, 2026. Dr. Liu, who holds an M.D. and Ph.D., will oversee clinical development, medical affairs, and regulatory functions. His extensive experience in immuno-oncology and history of advancing cancer therapies are expected to benefit the company significantly.
Read more →VIR▲ +3.1%today
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Vir Biotechnology announced it will present expanded results from the Phase 2 SOLSTICE trial at the AASLD The Liver Meeting 2026. The trial evaluates the efficacy of the combination of elebsiran and tobevibart for treating chronic hepatitis delta. This presentation is scheduled for November 5-9, 2026, in Denver, CO.
Read more →VIRVir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology has announced the appointment of Aziz Sawaf as its new Chief Financial Officer. This leadership change is expected to bring valuable experience and strategic financial oversight to the company. The appointment signals a focus on enhancing financial strategies as the company continues to grow.
Read more →VIR▲ +6.3%on this news
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology, Inc. announced that its CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for September 14 at 7:45 a.m. ET in New York City. A live webcast will be available and archived for 30 days.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology has released its corporate update and financial results for the second quarter of 2026. The company highlighted the importance of new therapies in improving awareness, testing, and access to care for the chronic hepatitis delta virus (CHD) community. Experts at EASL noted that achieving undetectable levels of the virus is crucial for better clinical outcomes.
Read more →VIR▼ -7%on this news
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology has announced a leadership transition with Brent Sabatini appointed as the Interim Principal Financial Officer. This change follows the departure of Jason O'Byrne, who will assist in the transition until August 3. The company is now conducting a search for a permanent CFO.
Read more →VIRVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology, Inc. has announced a conference call scheduled for August 5, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter. This call will provide a corporate update and is accessible via the company's website. The focus on financial transparency is likely to engage investors and stakeholders.
Read more →VIRVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology has appointed Timothy Coughlin to its Board of Directors. Coughlin's extensive experience in the biopharma industry is expected to enhance the company's leadership. This strategic move aims to bolster the company's governance and support its future initiatives.
Read more →VIRVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology will present complete data from the Phase 2 SOLSTICE clinical trial focused on Hepatitis Delta at the EASL Congress 2026. This presentation is expected to provide insights into the trial's findings and implications for future research. The event highlights the company's ongoing commitment to addressing Hepatitis Delta.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology has released a corporate update along with its financial results for the first quarter of 2026. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or corporate strategies are not disclosed in the provided text.
Read more →VIRVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology will participate in the Bank of America Securities 2026 Healthcare Conference. This event provides a platform for the company to discuss its strategies and advancements in biotechnology. Further details about the conference agenda and Vir's specific contributions are yet to be announced.
Read more →VIRVir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology, Inc. will host a conference call on May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter ending March 31, 2026. The call will provide a corporate update and can be accessed via the company's website. Vir is focused on developing treatments for infectious diseases and cancer.
Read more →VIRVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Biotechnology has finalized a global collaboration with Astellas for the development and commercialization of VIR-5500, a T-cell engager for metastatic prostate cancer. The agreement includes a $240 million upfront payment and potential milestone payments totaling up to $1.37 billion. Astellas will lead commercialization efforts in the U.S., while Vir retains co-promotion rights. The collaboration aims to enhance the drug's development towards market readiness.
Read more →VIR▲ +7.9%on this newsshared move
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology has initiated the dosing of the first patient in its Phase 1 trial for VIR-5500, a T-cell engager targeting metastatic prostate cancer. This trial will assess the safety and efficacy of VIR-5500 as both a monotherapy and in combination with an androgen receptor pathway inhibitor. The company is optimistic about the treatment's potential, supported by encouraging data from earlier studies.
Read more →VIRVir Biotechnology to Participate in Upcoming March 2026 Investor Conferences
Vir Biotechnology, Inc. has announced its participation in several investor conferences scheduled for March 2026. The management team will engage in live webcasts, which will be available for 30 days post-event. The company focuses on developing treatments for infectious diseases and cancer, showcasing its commitment to innovation in biopharmaceuticals.
Read more →VIR▼ -6.8%on this newsshared move
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology has announced the pricing of its public offering of 17,647,058 shares at $8.50 each, aiming to raise $150 million. The offering includes a 30-day option for underwriters to purchase additional shares. The closing is expected on February 27, 2026, pending customary conditions. This move supports Vir's mission to develop treatments for serious infectious diseases and cancer.
Read more →VIR▲ +5.4%on this newsshared move
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology, Inc. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The offering is part of their strategy to fund clinical programs targeting serious infectious diseases and cancer. The terms and completion of the offering depend on market conditions.
Read more →About Vir Biotechnology, Inc.
Headquarters1800 OWENS STREET, SAN FRANCISCO, CA, 94158
BIOPHARMAWATCH ELITE PLUS
Trade the next VIR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime